MADRIGAL PHARMACEUTICALS, INC. Business Finance Contracts & Agreements

Underwriting Agreement, dated September 28, 2023 (Filed With SEC on October 2, 2023)

Form of Pre-Funded Warrant (Filed With SEC on October 2, 2023)

Registration Rights Agreement, dated August 7, 2023, by and among Madrigal Pharmaceuticals, Inc., 667, L.P. and Baker Brothers Life Sciences, L.P (Filed With SEC on August 8, 2023)

Form of Restricted Stock Unit Agreement under Amended 2015 Stock Plan (Filed With SEC on February 23, 2023)

Form of Tranche 2 Warrant Agreement, dated February 3, 2023, by and among Madrigal Pharmaceuticals, Inc. and Hercules Capital, Inc. and affiliates (Filed With SEC on February 9, 2023)

Loan and Security Agreement, dated May 9, 2022, as amended by the First Amendment to Loan and Security Agreement, dated February 3, 2023, by and among Madrigal Pharmaceuticals,... (Filed With SEC on February 9, 2023)

Securities Purchase Agreement, dated December 21, 2022, by and among Madrigal Pharmaceuticals, Inc. and the institutional investors listed on the signature pages thereto (Filed With SEC on December 23, 2022)

Amendment No. 2, dated December 22, 2022, to Securities Purchase Agreement, dated June 20, 2017, by and among Madrigal Pharmaceuticals, Inc. and the investors listed on the... (Filed With SEC on December 23, 2022)

Form of Warrant Agreement, dated May 9, 2022, between Madrigal Pharmaceuticals, Inc. and Hercules Capital, Inc. and affiliates (Filed With SEC on August 4, 2022)

Loan and Security Agreement, dated May 9, 2022, by and among Madrigal Pharmaceuticals, Inc., Canticle Pharmaceuticals, Inc., the several banks and other financial institutions or... (Filed With SEC on August 4, 2022)

Form of Nonqualified Stock Option Agreement for Directors under Amended 2015 Stock Plan (Filed With SEC on August 6, 2020)

Underwriting Agreement, dated December 10, 2019, by and among Madrigal Pharmaceuticals, Inc., the Selling Stockholders, and Goldman Sachs & Co. LLC (Filed With SEC on December 12, 2019)

Underwriting Agreement, dated June 6, 2018, by and between Madrigal Pharmaceuticals, Inc, Goldman Sachs & Co. LLC as Representative of the Underwriters set forth therein, and the... (Filed With SEC on June 8, 2018)

Underwriting Agreement, dated December 18, 2017, by and between Madrigal Pharmaceuticals, Inc. and Goldman Sachs & Co. LLC as Representative of the Underwriters set forth therein (Filed With SEC on December 21, 2017)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 21, 2017)

MADRIGAL PHARMACEUTICALS, INC. AMENDED 2015 STOCK PLAN (Filed With SEC on July 22, 2016)

SYNTA PHARMACEUTICALS CORP. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Companys 2015 Stock Plan (Filed With SEC on May 10, 2016)

ELEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on November 5, 2015)

SYNTA PHARMACEUTICALS CORP. 2015 STOCK PLAN (Filed With SEC on June 15, 2015)

22,000,000 Shares Synta Pharmaceuticals Corp. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 1, 2015)

RESTRICTED STOCK AGREEMENT SYNTA PHARMACEUTICALS CORP. (Filed With SEC on March 12, 2015)

RESTRICTED STOCK AGREEMENT SYNTA PHARMACEUTICALS CORP. (Filed With SEC on November 6, 2014)

SYNTA PHARMACEUTICALS CORP. Common Stock (par value $0.0001 per share) At the Market Issuance Sales Agreement (Filed With SEC on July 18, 2014)

TENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on July 18, 2014)

SYNTA PHARMACEUTICALS CORP. Common Stock (par value $0.0001 per share) At the Market Issuance Sales Agreement (Filed With SEC on May 8, 2014)

SUBSCRIPTION AGREEMENT (Filed With SEC on April 14, 2014)

NINTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on December 2, 2013)

14,000,000 Shares Synta Pharmaceuticals Corp. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on November 14, 2013)

EIGHTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on April 1, 2013)

AMENDED AND RESTATED PROMISSORY NOTE March 28, 2013 $12,500,000 (Filed With SEC on April 1, 2013)

AMENDED AND RESTATED PROMISSORY NOTE March 28, 2013 $10,000,000 (Filed With SEC on April 1, 2013)

SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on March 14, 2013)

SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on December 20, 2012)

COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on December 13, 2012)

FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on August 2, 2012)

SUBSCRIPTION AGREEMENT (Filed With SEC on July 26, 2012)

SYNTA PHARMACEUTICALS CORP. Common Stock (par value $0.0001 per share) At the Market Issuance Sales Agreement (Filed With SEC on May 3, 2012)

FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on February 22, 2012)

7,000,000 Shares Synta Pharmaceuticals Corp. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on January 6, 2012)